Difference between revisions of "Androgen receptor"

From Libre Pathology
Jump to navigation Jump to search
Line 1: Line 1:
{{ Infobox immunostain
| Name      = {{PAGENAME}}
| Image      =
| Width      =
| Caption    =
| Abbrev    =
| Synonyms  =
| Similar    =
| Clones    =     
| Use        =
| Subspecial = 
| Pattern    = nuclear
| Positive  = [[salivary duct carcinoma]], [[Brenner tumour]], [[apocrine carcinoma of the breast]], [[prostate carcinoma]] (most cases)
| Negative  =
| Other      =
}}
'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens (testosterone, dihydrotestosterone).
'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens (testosterone, dihydrotestosterone).



Revision as of 01:36, 10 February 2016

Androgen receptor
Immunostain in short
Normal staining pattern nuclear
Positive salivary duct carcinoma, Brenner tumour, apocrine carcinoma of the breast, prostate carcinoma (most cases)

Androgen receptor, abbreviated AR, is receptor activated by androgens (testosterone, dihydrotestosterone).

Tumours with AR

See also

References

  1. Fan, CY.; Wang, J.; Barnes, EL. (Apr 2000). "Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.". Am J Surg Pathol 24 (4): 579-86. PMID 10757407.
  2. Kuhn, E.; Ayhan, A.; Shih, IeM.; Seidman, JD.; Kurman, RJ. (Dec 2013). "Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium.". Eur J Cancer 49 (18): 3839-49. doi:10.1016/j.ejca.2013.08.011. PMID 24012099.
  3. Honma, N.; Takubo, K.; Akiyama, F.; Sawabe, M.; Arai, T.; Younes, M.; Kasumi, F.; Sakamoto, G. (Aug 2005). "Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.". Histopathology 47 (2): 195-201. doi:10.1111/j.1365-2559.2005.02181.x. PMID 16045781.